{"id":"placebo-then-pioglitazone","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Weight gain"},{"rate":"5-10","effect":"Fluid retention / edema"},{"rate":"variable","effect":"Hypoglycemia (when combined with other agents)"},{"rate":"5","effect":"Headache"},{"rate":"5","effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pioglitazone is a thiazolidinedione that binds to PPAR-γ, a nuclear receptor involved in glucose and lipid metabolism. By activating PPAR-γ, it increases insulin sensitivity in muscle and adipose tissue, reduces hepatic glucose production, and improves glycemic control. This mechanism makes it effective for managing type 2 diabetes, particularly in insulin-resistant patients.","oneSentence":"Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:28.832Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05305287","phase":"PHASE4","title":"Quantifying Hepatic Mitochondrial Fluxes in Humans","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2022-11-01","conditions":"Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders","enrollment":60},{"nctId":"NCT07056699","phase":"PHASE3","title":"SGLT2i, Pioglitazone, and Ketone Production in T1D","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-01-30","conditions":"Type1diabetes","enrollment":24},{"nctId":"NCT06336798","phase":"PHASE2","title":"Bioenergetic Effect of Pioglitazone in CLD-PH","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-12-17","conditions":"Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases","enrollment":20},{"nctId":"NCT00843791","phase":"NA","title":"Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin","status":"TERMINATED","sponsor":"Oregon Health and Science University","startDate":"2009-02","conditions":"Obesity, Insulin Resistance","enrollment":6},{"nctId":"NCT00745225","phase":"PHASE4","title":"Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2006-02","conditions":"End-stage Renal Disease","enrollment":160},{"nctId":"NCT02338999","phase":"PHASE1, PHASE2","title":"Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)","status":"COMPLETED","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2015-06-18","conditions":"Systemic Lupus Erythematosus","enrollment":88},{"nctId":"NCT04662866","phase":"PHASE2","title":"Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2021-02-10","conditions":"Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders","enrollment":64},{"nctId":"NCT00694759","phase":"NA","title":"Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2006-10","conditions":"Polycystic Ovary Syndrome","enrollment":37},{"nctId":"NCT00770367","phase":"PHASE4","title":"Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2008-10","conditions":"Diabetes","enrollment":36},{"nctId":"NCT00994175","phase":"PHASE2","title":"A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2009-09-23","conditions":"Severe, Refractory Asthma, Airway Inflammation, Airflow Obstruction","enrollment":15},{"nctId":"NCT00300365","phase":"PHASE2","title":"Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2005-11","conditions":"Metabolic Syndrome","enrollment":38},{"nctId":"NCT00634036","phase":"PHASE2","title":"Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics","status":"COMPLETED","sponsor":"Fernando Holguin","startDate":"2009-10","conditions":"Asthma","enrollment":23},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT00481663","phase":"PHASE2","title":"A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-08-19","conditions":"Type II Diabetes Mellitus","enrollment":555},{"nctId":"NCT00554853","phase":"PHASE3","title":"PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2007-11","conditions":"Rheumatoid Arthritis","enrollment":143},{"nctId":"NCT00745914","phase":"NA","title":"Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2008-09","conditions":"Endstage Renal Disease, Diabetes","enrollment":22},{"nctId":"NCT00763815","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-09","conditions":"Diabetes Mellitus Type 2","enrollment":484},{"nctId":"NCT00975286","phase":"PHASE3","title":"24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":446},{"nctId":"NCT01301027","phase":"NA","title":"Effect of Adipokines in Hemodialysis Patients","status":"COMPLETED","sponsor":"University of Utah","startDate":"2008-05","conditions":"End Stage Renal Disease","enrollment":95},{"nctId":"NCT01134835","phase":"PHASE4","title":"PPAR-gamma: a Novel Therapeutic Target for Asthma?","status":"TERMINATED","sponsor":"University of Nottingham","startDate":"2010-06","conditions":"Asthma","enrollment":68},{"nctId":"NCT01759823","phase":"PHASE2, PHASE3","title":"Bone Marrow Derived Stem Cell Transplantation in T2DM","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2012-12","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT01065298","phase":"","title":"Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT00827892","phase":"PHASE2","title":"Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2009-03","conditions":"Intracerebral Hemorrhage","enrollment":84},{"nctId":"NCT00787644","phase":"PHASE2","title":"Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)","status":"TERMINATED","sponsor":"University of Vermont","startDate":"2009-01","conditions":"Asthma, Obesity","enrollment":28},{"nctId":"NCT00763139","phase":"NA","title":"Inflammation and Insulin Resistance in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2009-04","conditions":"Rheumatoid Arthritis","enrollment":34},{"nctId":"NCT00811681","phase":"PHASE3","title":"Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-12","conditions":"Friedreich's Ataxia","enrollment":40},{"nctId":"NCT00408850","phase":"PHASE3","title":"Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity","status":"UNKNOWN","sponsor":"Baker Heart Research Institute","startDate":"2008-11","conditions":"Metabolic Syndrome","enrollment":44},{"nctId":"NCT01109030","phase":"PHASE2, PHASE3","title":"Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2010-04","conditions":"Major Depressive Disorder","enrollment":50},{"nctId":"NCT00708175","phase":"PHASE4","title":"Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-05","conditions":"Bone Metabolism","enrollment":156},{"nctId":"NCT00656864","phase":"PHASE4","title":"Pioglitazone Incretin Study","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2008-05","conditions":"Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT00772174","phase":"PHASE3","title":"Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Diabetes Mellitus","enrollment":418}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":706,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Actos, Glustin, Zactos"],"phase":"marketed","status":"active","brandName":"Placebo then Pioglitazone","genericName":"Placebo then Pioglitazone","companyName":"Medical University of South Carolina","companyId":"medical-university-of-south-carolina","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}